Innovative Diagnostics ID Screen® SARS-CoV-2-N Indirect ELISA

A highly reliable serology test to detect IgG antibodies against SARS-CoV-2.

Indirect semi-quantitative ELISA for the specific detection of IgG antibodies against the nucleocapsid of SARS-CoV-2 in human serum and plasma.

  • Approved by French authorities further to its evaluation by the French National Reference Centre
  • High sensitivity and specificity (99.9%) ensures accurate results, with clear discrimination of positive and negative samples
  • Excellent specificity and high positive predictive value, even in low prevalence areas, means a positive result reliably indicates if a person has been exposed to the virus and if the patient has developed antibodies

Rapid and easy-to-use:

  • Use manually or with any open automated immunoassay platform
  • Ready-to-use reagents
  • Results in 95 minutes
  • Possibility to operate on inactivated serum/plasma samples to guarantee operator’s safety

This product is CE marked and available for immediate shipping.


Method Semi-quantitative indirect ELISA
Species Humans
Specimens Serum or plasma
Coated antigen Purified recombinant antigen
Conjugate Protein G-HRP conjugate (concentrated 10X)

Download Flyer ▸